Molecular Partners AG/Fr. MOLN
08:00
10:05
12:10
14:15
16:20
1D1W1MYTD1Y5YMAX
About Molecular Partners AG
Molecular Partners AG is a biotechnology company specializing in the development of targeted protein therapeutics known as DARPin® molecules. These molecules are designed to modulate protein-protein interactions, providing potential treatments for a range of diseases, including cancer, ophthalmology, and infectious diseases. Founded in 2004, the company is headquartered in Zurich, Switzerland. Molecular Partners emphasizes its proprietary DARPin® technology as a competitive strength, offering advantages in selectivity and versatility compared to traditional antibodies. Its strategic focus includes advancing its pipeline of drug candidates through clinical trials and collaborating with major pharmaceutical firms for development and commercialization.
Ticker
Fr. MOLN
Sector
Primary listing
XSWX
Employees
159
Headquarters
Schlieren, Switzerland
Website
MOLN Metrics
BasicAdvanced
CHF 138M
-
-CHF 1.62
0.56
-
Price and volume
Market cap
CHF 138M
Beta
0.56
52-week high
CHF 4.44
52-week low
CHF 2.70
Average daily volume
21K
Financial strength
Current ratio
9.28
Quick ratio
9.081
Long term debt to equity
0.322
Total debt to equity
1.604
Interest coverage (TTM)
-3,197.94%
Profitability
EBITDA (TTM)
-56.742
Management effectiveness
Return on assets (TTM)
-27.01%
Return on equity (TTM)
-51.41%
Valuation
Price to book
1.45
Price to tangible book (TTM)
1.45
Price to free cash flow (TTM)
-2.551
Free cash flow yield (TTM)
-39.20%
Free cash flow per share (TTM)
-1.454
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-14.33%
3-year earnings per share growth (CAGR)
-23.03%
10-year earnings per share growth (CAGR)
16.71%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Molecular Partners AG stock?
Molecular Partners AG (MOLN) has a market cap of Fr.138M as of February 21, 2026.
What is the P/E ratio for Molecular Partners AG stock?
The price to earnings (P/E) ratio for Molecular Partners AG (MOLN) stock is 0 as of February 21, 2026.
Does Molecular Partners AG stock pay dividends?
No, Molecular Partners AG (MOLN) stock does not pay dividends to its shareholders as of February 21, 2026.
When is the next Molecular Partners AG dividend payment date?
Molecular Partners AG (MOLN) stock does not pay dividends to its shareholders.
What is the beta indicator for Molecular Partners AG?
Molecular Partners AG (MOLN) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.